A laboratory reported that samples from a patient tested on the bioplex 2200 syphilis total & rpr kit in (b)(6) and (b)(6) 2021 were (b)(6) total and (b)(6) assays.The samples were sent out for confirmatory testing at (b)(6) labs with an elisa syphilis igg assay and at both times, the samples were (b)(6).The physician decided to administer penicillin to the patient based on the bioplex results.However, the physician expressed concern that the bioplex results were (b)(6), while the syphilis igg eia results from (b)(6) were (b)(6). investigation by the bio-rad product support and technical support found no issues with the instrument.The affected bioplex 2200 syphilis total & rpr, lot 301210 is performing within specification, however, the lot was withdrawn from the market on september 17th because of trends observed in routine stability monitoring that indicate the kit performance will eventually fall below specifications prior to the expiration date.Additionally, bio-rad has recently alerted users that interference can occur in patients who have been recently received the covid-19 vaccine. vaccine interference is a known limitation for this assay and is already indicated in the labeling. the vaccination status of the patient is unknown, and the doctor is aware of the potential for increased rpr response due to recent covid-19 vaccination.Per the ifu, test results should be considered with other laboratory results as well as the clinical presentation of the patient.Results should be interpreted by a physician. the bioplex 2200 syphilis total assay measures both igm and igg antibodies.The method used to confirm at the (b)(6) laboratory only measure igg antibodies.The bioplex 2200 syphilis total results may correctly identified the presence of igm antibodies, however, bio-rad was unable to obtain patient samples for investigation to confirm.Therefore, out of an abundance of caution, and due to concern expressed by the physician, bio-rad is reporting this case as an adverse event for potential unnecessary treatment with penicillin.
|
A laboratory reported that samples from a patient tested on the bioplex 2200 syphilis total & rpr kit in (b)(6) and (b)(6) 2021 were (b)(6) total and (b)(6) assays.The samples were sent out for confirmatory testing at (b)(6) labs with an elisa syphilis igg assay and at both times, the samples were (b)(6).The physician decided to administer penicillin to the patient based on the bioplex results.However, the physician expressed concern that the bioplex results were (b)(6), while the (b)(6) results from (b)(6) were (b)(6). .
|